LONDON, UK: Physiomics plc, the consultancy using mathematical models to support the development of drug treatment regimens and personalised medicine solutions, announced that Hayley Close has today joined the Company as Head of Business Development.
Hayley holds a degree in Biomedical Science from University College London and joins us from Fusion Antibodies plc where she was Key Account Manager responsible for identifying and engaging with new clients and developing existing business globally.
At Physiomics, Hayley will work directly with the CEO and senior management team with the aim of significantly expanding both existing and new business.
Dr Jim Millen, CEO, commented “Physiomics has reached the stage of its growth where we believe there will be real benefit in retaining a full-time business development executive. Hailey joins us with a fantastic track-record and we look forward to working with her to significantly expand Physiomics’ business”.
Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions. The Company’s Virtual Tumour technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost.
The predictive capability of Physiomics’ technologies have been confirmed by over 80 projects, involving over 40 targets and 70 drugs, and has worked with clients such as Merck KGaA, Astellas, Merck & Co and Bicycle Therapeutics.
Physiomics Plc share price
7.00 GBX0.00 (0.00%)today
27 Aug, 3:41 pm GMT+1 ·Disclaimer
Leave a Reply